Gap19: Selective Connexin 43 Hemichannel Blocker for Neuroprotection and Immune Modulation

Executive Summary: Gap19, available from APExBIO, is a peptide-based, highly selective inhibitor of connexin 43 (Cx43) hemichannels (IC50 ≈ 50 μM), sparing gap junction channels and enabling targeted modulation of neuroglial and immune signaling (Wu et al., 2020, APExBIO). Gap19 blocks ATP release in astrocytes (IC50 = 142 μM) and demonstrates neuroprotection in mouse cerebral ischemia models (300 μg/kg, i.c.v.), reducing infarct volume, neuronal damage, and functional deficits. The TAT-conjugated variant extends utility to intraperitoneal administration (25 mg/kg, 4 h post-reperfusion), implicating the JAK2/STAT3 pathway. Gap19’s solid form, high water solubility (≥58.07 mg/mL), and recommended -20°C storage streamline reproducible experimental workflows.

Biological Rationale

Connexin 43 (Cx43) is a ubiquitously expressed gap junction protein forming both gap junction channels and hemichannels. Cx43 hemichannels mediate ATP and small molecule release from astrocytes and immune cells, impacting neuroglial interaction, inflammation, and tissue injury (Wu et al., 2020). Excessive hemichannel opening contributes to neurotoxicity, neuroinflammation, and tissue damage, particularly in stroke and ischemia/reperfusion injury. Selective inhibition of Cx43 hemichannels, without disrupting canonical gap junction communication, is a critical research goal. Gap19 addresses this need by specifically targeting the cytoplasmic loop domain of Cx43, minimizing off-target effects (Gap19: Selective Connexin 43 Hemichannel Blocker for Neuroinflammation). This article builds upon and clarifies these neuroglial mechanisms by detailing recent in vivo and immunomodulatory findings.

Mechanism of Action of Gap19

Gap19 is a peptide sequence derived from the intracellular cytoplasmic loop of Cx43. It selectively binds and inhibits Cx43 hemichannels, blocking their open state while sparing gap junction channels (APExBIO). The peptide does not disrupt Cx43 gap junction intercellular communication, enabling dissection of hemichannel-specific functions (Gap19: Selective Connexin 43 Hemichannel Blocker for Neuroinflammation). In neuroglia, Gap19 inhibits ATP release in a dose-dependent manner (IC50 = 142 μM, primary cortical astrocytes, 37°C, 5% CO₂), suppressing downstream purinergic signaling. In immune cells, such as RAW264.7 macrophages, Gap19 attenuates angiotensin II-induced M1 polarization and inflammatory cytokine production by interfering with the Cx43/NF-κB axis (Wu et al., 2020).

Evidence & Benchmarks

• Gap19 exhibits an IC50 of ~50 μM for Cx43 hemichannel inhibition, with negligible effect on gap junction channels under physiological conditions (APExBIO).
• In primary cultured cortical astrocytes, Gap19 inhibits ATP release in a dose-dependent manner (IC50 = 142 μM, 37°C, 5% CO₂) (Wu et al., 2020).
• In a mouse model of middle cerebral artery occlusion (MCAO), intracerebroventricular Gap19 (300 μg/kg) reduces infarct volume and neurological deficits (24 h post-occlusion) (APExBIO).
• The TAT-Gap19 conjugate confers neuroprotection after intraperitoneal injection (25 mg/kg, 4 h post-reperfusion), implicating the JAK2/STAT3 pathway (APExBIO).
• Gap19 attenuates AngII-induced M1 macrophage polarization and associated pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6, CD86) in RAW264.7 cells via Cx43/NF-κB inhibition (Wu et al., 2020).
• Gap19 demonstrates robust water solubility (≥58.07 mg/mL) and is stable at -20°C for solid storage (APExBIO).
• Previous reviews detail reproducibility and selectivity advantages over other Cx43 inhibitors (Gap19 (SKU B4919): Reliable Cx43 Hemichannel Inhibition for Cell Assays), which this article extends by documenting JAK2/STAT3 pathway involvement.

Applications, Limits & Misconceptions

Applications

• Modeling of neuroprotection in stroke, ischemia/reperfusion, and traumatic brain injury studies.
• Dissection of neuroglial ATP signaling and purinergic receptor activation in vitro (primary astrocytes, microglia).
• Immunomodulation research, especially in inflammation and atherosclerosis models involving macrophage polarization.
• Translational pathway studies, including JAK2/STAT3 signaling modulation in vivo.

Common Pitfalls or Misconceptions

• Gap19 does not block Cx43 gap junction channels—only hemichannels are affected (APExBIO).
• It is ineffective against other connexin isoforms (e.g., Cx32, Cx36), limiting use to Cx43-specific studies.
• Gap19 is not stable in ethanol and should not be dissolved or stored in ethanol-containing solutions.
• Peptide solutions are for short-term use only; long-term storage requires lyophilized solid at -20°C.
• Systemic neuroprotection with unconjugated Gap19 is not achieved via peripheral administration; TAT-conjugation is required for blood-brain barrier penetration (APExBIO).

Workflow Integration & Parameters

Gap19 (SKU B4919) from APExBIO is provided as a solid (MW 1161.45, C55H96N14O13), highly soluble in water (≥58.07 mg/mL) and DMSO (≥26.55 mg/mL). For in vitro assays, recommended working concentrations range from 10–200 μM, with dose-dependent inhibition of Cx43 hemichannels. For in vivo neuroprotection, intracerebroventricular administration at 300 μg/kg (mouse, post-MCAO) is supported; for systemic delivery, use TAT-Gap19 at 25 mg/kg (i.p., within 4 h post-reperfusion). Store lyophilized Gap19 at -20°C; reconstituted solutions should be used promptly. Product ordering and full technical documentation are accessible via the Gap19 product page.

This article extends previous guides (Advanced Insights into Selective Connexin 43 Hemichannel Blockade) by detailing workflow parameters for both in vitro and in vivo applications, including JAK2/STAT3 pathway targeting.

Conclusion & Outlook

Gap19 is a rigorously validated, selective Cx43 hemichannel inhibitor peptide. It is a benchmark tool for neuroprotection, neuroglial signaling, and immune modulation research in ischemia, stroke, and inflammatory models. Its precise mechanism, robust solubility, and workflow compatibility—coupled with APExBIO's quality assurance—enable reproducible, translational experimentation. Ongoing studies continue to elucidate the therapeutic impact of hemichannel blockade in diverse pathologies, with Gap19 at the forefront of these efforts.